Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART

Autor: Rusconi, S., Vitiello, P., Adorni, F., Ferramosca, S., Foca, E., Capetti, A., Meraviglia, P., Quirino, T., Bonora, S., D Annunzio, M., Antonio Di Biagio, Di Pietro, M., Butini, L., Orofino, G., Colafigli, M., Vullo, V., Francisci, D., Andreoni, M., Merlini, E., Marchetti, G.

Publikováno v: Infection 38 (2010): 13–13.
info:cnr-pdr/source/autori:Rusconi, S.; Vitiello, P.; Adorni, F.; Ferramosca, S.; Foca, E.; Capetti, A.; Meraviglia, P.; Quirino, T.; Bonora, S.; D'Annunzio, M.; Di Biagio, A.; Di Pietro, M.; Butini, L.; Orofino, G.; Colafigli, M.; Vullo, V.; Francisci, D.; Andreoni, M.; Merlini, E.; Marchetti, G./titolo:Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART/doi:/rivista:Infection/anno:2010/pagina_da:13/pagina_a:13/intervallo_pagine:13–13/volume:38
Publons

Background: Under HAART, 7-39% of HIV-infected patients (pts) fail to exhibit a recovery in CD4 cells despite full suppression of viral replication. In MOTIVATE trials, MVC was superior to OBT in increasing CD4 cells in ARV-experienced pts. This stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1cab8bc08ac7f4094b5f08a4ea43fafd
https://publications.cnr.it/doc/353230